Patient survival, disease recurrence and tumour pathology following preoperative treatment with anti-oestrogen therapies using a single dose of Faslodex [fulvestrant] or tamoxifen therapy in postmenopausal women prior to surgery for primary breast cancer

Trial Profile

Patient survival, disease recurrence and tumour pathology following preoperative treatment with anti-oestrogen therapies using a single dose of Faslodex [fulvestrant] or tamoxifen therapy in postmenopausal women prior to surgery for primary breast cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 15 May 2006

At a glance

  • Drugs Fulvestrant; Tamoxifen
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 May 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top